1: Kirchhoff E, Schneider V, Pichler G, Reif P, Haas J, Joksch M, Mager C, Schmied C, Schöll W, Pichler-Stachl E, Gold D. Hexoprenaline Compared with Atosiban as Tocolytic Treatment for Preterm Labor. Geburtshilfe Frauenheilkd. 2022 Aug 10;82(8):852-858. doi: 10.1055/a-1823-0176. 2: Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. 3: Mayer M, Minichmayr A, Klement F, Hroncek K, Wertaschnigg D, Arzt W, Wiesinger-Eidenberger G, Lechner E. Tocolysis with the β-2-sympathomimetic hexoprenaline increases occurrence of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2013 Mar;98(2):F108-11. doi: 10.1136/archdischild-2011-301030. Epub 2012 May 18.